Abstract:Abstract Introduction Metabolic impairments and sleep disruptions are both recognized as modifiable risk factors in the development of Alzheimer’s disease (AD). A bidirectional relationship exists between sleep and AD where pathology can disrupt sleep, but sleep disturbances can also increase AD-related pathology. This results in a feed-forward cycle of disease progression and further sleep impairments. Sleep fragmentation and poor sleep quality can also cause glucose intolerance and insulin resistance. However, it remains unclear if peripheral metabolic dysfunction alone can impair sleep, particularly in the context of AD-related pathology. Therefore, the goal of this study was to establish mechanisms connecting peripheral metabolic and sleep disruptions and identify potential therapeutic targets for mitigating AD risk. Methods We implanted biosensors measuring interstitial fluid (ISF) levels of glucose and lactate, biomarkers of cerebral metabolism and neuronal activity, respectively, directly into the hippocampus of wildtype and APP/PS1 mice, a model of amyloid-beta (Aβ) overexpression. Biosensors were paired with cortical EEG and EMG recordings for simultaneous sleep/wake analysis. To understand the relationship between metabolic dysfunction and sleep, we altered the peripheral metabolic environment using two paradigms: an acute high-fat, high-sugar diet (HF/HSD) and a pharmacological metabolic rescue. Results We found short-term HF/HSD exposure was sufficient to disrupt ISF glucose and lactate diurnal rhythms, independent of changes to pathology burden. Moreover, we found significant sleep disruptions, particularly decreased delta power, indicating slow wave sleep impairments. These findings were exacerbated in mice with Aβ pathology who have disrupted metabolic and sleep functioning at baseline. Conversely, we found normalizing peripheral glucose tolerance in mice with Aβ pathology was sufficient to rescue impaired ISF glucose and lactate rhythms. We also saw a restoration of normal sleep-wake patterns, specifically within slow wave activity. Conclusion We found modulating peripheral glucose metabolism can bidirectionally alter sleep, particularly slow wave sleep, independent of changes in Aβ burden. This indicates sleep as a mediator in the relationship between metabolic impairments and AD pathophysiology. While impaired sleep increases AD risk, improved sleep slows pathology accumulation. Therefore, this study demonstrates targeting peripheral glucose regulation is a potential avenue for early AD intervention and risk mitigation. Support (if any) F31-AG066302, R01-AG068330, P30-AG072947

0225 Effect of thermoneutral temperature exposure in the APP/PS1 knock-in mouse model of Alzheimer’s disease

Thermoneutral Temperature Exposure Enhances Slow Wave Sleep with a Correlated Improvement in Amyloid Pathology in a Triple-Transgenic Mouse Model of Alzheimer’s Disease

0415 Metabolic Dysfunction and Sleep Disruption in Models of Alzheimer’s Disease

0085 Peripheral glucose metabolism bidirectionally modulates sleep in a model of Alzheimer's disease

Lateralized brunt of sleep deprivation on white matter injury in a rat model of Alzheimer's disease

0216 Behavioral State Recording & Sleep Deprivation in Mice to Explore the Underlying Mechanisms of Alzheimer’s Disease

Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles

0429 Chronic Sleep Disturbance Causes Cognitive Impairment and Alzheimer’S Disease-Like Neuropathology

0215 Optogenetic Rescue of Sleep Slows Alzheimer's Progression in a Mouse Model

Thermotherapy has Sexually Dimorphic Responses in APP/PS1 Mice

The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L).

Interactions between sleep disturbances and Alzheimer's disease on brain function: a preliminary study combining the static and dynamic functional MRI.

Altered sleep behavior strengthens face validity in the ArcAβ mouse model for Alzheimer's disease

Disturbance of REM sleep exacerbates microglial activation in APP/PS1 mice

Reduced slow-wave activity and autonomic dysfunction during sleep precede cognitive deficits in Alzheimer’s disease transgenic mice

Longitudinal assessment of aggression and circadian rhythms in the APPswe mouse model of Alzheimer`s disease

Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.

Sleep and diurnal rest-activity rhythm disturbances in a mouse model of Alzheimer's disease

Amyloid beta-independent sleep markers associated with early regional tau burden and cortical thinning

Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics

1008 Daytime Sleepiness Is Associated with Increased Cerebrospinal Fluid Tau Proteins in Alzheimer’s Disease